Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morning versus evening dosing of GLPG3067 + GLPG2222 + GLPG2737 in healthy women
NL-OMON44378Phase 1Active, not recruiting
- Sponsor
- Galapagos NV
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of navocaftor, galicaftor and GLPG2737 in cystic fibrosis (CF) (2 arms), sponsored by Galapagos NV. Primary endpoint: Pharmacokinetic parameters of GLPG3067, GLPG2222, and GLPG2737. Started Dec 2017; status: active, not recruiting.
02
Drugs
navocaftorgalicaftorGLPG2737
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON44378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44378.